Erythropoietin-Mimetic Peptide 17 (EMP17)

Erythropoietin-Mimetic Peptide 17 (EMP17) (CPC catalog code SIGN-004) is a synthetic cell-signaling research peptide in the signaling category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.

Published and internal research programs use Erythropoietin-Mimetic Peptide 17 (EMP17) as a reference standard in signaling workflows — for example, protein–protein interaction (ppi) mapping and sh2, sh3, pdz, and 14-3-3 binding studies. Human clinical evidence is not established.

No. Erythropoietin-Mimetic Peptide 17 (EMP17) is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.

In a signaling workflow, Erythropoietin-Mimetic Peptide 17 (EMP17) is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. SPR, BLI, AlphaScreen, and pulldown / Western readouts.

Store lyophilized at −20 °C. Aliquot in DMSO or aqueous buffer per solubility. Follow your institution's standard operating procedures for handling synthetic peptides.

This kindr reference page mirrors CPC Scientific's catalog metadata for SIGN-004. The upstream reference sheet — including sequence, purity, MW, and application notes where published — is linked from the buy panel. All orders placed on kindr Peptides ship internationally under research-use terms only.

Research-grade peptides in the CPC catalog are synthesized by solid-phase peptide synthesis (SPPS), purified by preparative RP-HPLC, and characterized by analytical HPLC and mass spectrometry. Typical purity is ≥95%; certificate of analysis is available on request.